-
- 抗原 See all FANCL 抗体
- FANCL (Fanconi Anemia, Complementation Group L (FANCL))
-
抗原表位
- AA 274-302, C-Term
-
适用
- 人
-
宿主
- 兔
-
克隆类型
- 多克隆
-
标记
- This FANCL antibody is un-conjugated
-
应用范围
- Western Blotting (WB)
- 纯化方法
- This antibody is purified through a protein A column, followed by peptide affinity purification.
- 免疫原
- This FANCL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 274-302 amino acids from the C-terminal region of human FANCL.
- 克隆位点
- RB23901
- 亚型
- Ig Fraction
- Top Product
- Discover our top product FANCL Primary Antibody
-
-
- 应用备注
- WB: 1:1000
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 缓冲液
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
- 储存液
- Sodium azide
- 注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- 4 °C,-20 °C
- 有效期
- 6 months
-
-
FAVL elevation in human tumors disrupts Fanconi anemia pathway signaling and promotes genomic instability and tumor growth." in: The Journal of clinical investigation, Vol. 120, Issue 5, pp. 1524-34, (2010) (PubMed).
: "Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer ..." in: Carcinogenesis, Vol. 30, Issue 11, pp. 1898-902, (2009) (PubMed).
: "FANCI binds branched DNA and is monoubiquitinated by UBE2T-FANCL." in: The Journal of biological chemistry, Vol. 284, Issue 35, pp. 23182-6, (2009) (PubMed).
: "Polymorphic variants in hereditary pancreatic cancer genes are not associated with pancreatic cancer risk." in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Vol. 18, Issue 9, pp. 2549-52, (2009) (PubMed).
: "Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia." in: Cellular oncology : the official journal of the International Society for Cellular Oncology, Vol. 30, Issue 4, pp. 299-306, (2008) (PubMed).
: "
-
FAVL elevation in human tumors disrupts Fanconi anemia pathway signaling and promotes genomic instability and tumor growth." in: The Journal of clinical investigation, Vol. 120, Issue 5, pp. 1524-34, (2010) (PubMed).
-
- 抗原
- FANCL (Fanconi Anemia, Complementation Group L (FANCL))
- 别名
- FANCL (FANCL 产品)
- 别名
- FAAP43 antibody, PHF9 antibody, POG antibody, 2010322C19Rik antibody, AW554273 antibody, B230118H11Rik antibody, Phf9 antibody, Pog antibody, gcd antibody, Fanconi anemia complementation group L antibody, Fanconi anemia, complementation group L antibody, FANCL antibody, Fancl antibody
- 背景
- The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity, they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group L. Alternative splicing results in two transcript variants encoding different isoforms.
- 分子量
- 42905
- NCBI登录号
- NP_001108108, NP_060532
- UniProt
- Q9NW38
- 途径
- DNA Damage Repair
-